Preclinical Gene Therapy Studies for Hemophilia Using Adeno-Associated Virus (AAV) Vectors

Gene therapy offers a potential cure for hemophilia and several gene transfer vectors have been evaluated for their ability to treat this disease. This article reviews the studies that have been performed to evaluate the ability of recombinant adeno-associated virus (AAV) vectors to achieve safely the sustained expression of clotting factors following intramuscular, intravenous, and intrahepatic delivery to several animal models. These routes of administration are all effective in providing sustained and therapeutic levels of factor IX (FIX), although the levels vary. Intrahepatic delivery is more efficacious than intravenous administration, which is superior to intramuscular delivery. The recent development of efficient factor VIII (FVIII) expression cassettes has made AAV-based gene therapy for hemophilia A also within reach. Although no acute toxicity has been observed with any route of administration, an increased risk of antibody formation against FIX has been noted following intramuscular delivery. Biodistribution studies concluded that the vector disseminates to most tissues in a dose-dependent and time-dependent manner, but the majority of the vector resides in the targeted tissue. In addition, the risk of germline transmission has been shown to be low or absent. The relatively recent isolation of new AAV serotypes has resulted in the identification of vectors that have enhanced tropism for certain tissues. This combined with the potential of these new vectors to evade the immune response to AAV2, makes them attractive candidates for gene therapy. Although much progress has been made using AAV to treat hemophilia, there are several outstanding issues that need to be addressed. Delivery of AAV to large animals has not been reproducible, which could be due to nonoptimized delivery and/or immune responses to the vector or transgene product. In addition, a complete understanding of the biology of these vectors is required to assess their long-term safety. Solving these issues will lead to the development of a successful gene therapy product.

KEYWORDS

Adeno-associated virus - vector - factor IX - FIX - factor VIII - FVIII

REFERENCES

• 1 Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells.  Curr Top Microbiol Immunol. 1992;  158 97-129
• 2 Xiao X, Li J, Samulski R J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.  J Virol. 1996;  70 8098-8108
• 3 Kessler P D, Podsakoff G M, Chen X et al.. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.  Proc Natl Acad Sci USA. 1996;  93 14082-14087
• 4 Herzog R W, Hagstrom J N, Kung S H et al.. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.  Proc Natl Acad Sci USA. 1997;  94 5804-5809
• 5 Nathwani A C, Davidoff A, Hanawa H, Zhou J F, Vanin E F, Nienhuis A W. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.  Blood. 2001;  97 1258-1265
• 6 Ge Y, Powell S, Van Roey M, McArthur J G. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.  Blood. 2001;  97 3733-3737
• 7 Fields P A, Kowalczyk D W, Arruda V R et al.. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.  Mol Ther. 2000;  1 225-235
• 8 Fields P A, Arruda V R, Armstrong E et al.. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.  Mol Ther. 2001;  4 201-210
• 9 Evans J P, Brinkhous K M, Brayer G D, Reisner H M, High K A. Canine hemophilia B resulting from a point mutation with unusual consequences.  Proc Natl Acad Sci USA. 1989;  86 10095-10099
• 10 Herzog R W, Yang E Y, Couto L B et al.. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.  Nat Med. 1999;  5 56-63
• 11 Herzog R W, Fields P A, Arruda V R et al.. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.  Hum Gene Ther. 2002;  13 1281-1291
• 12 Mauser A E, Whitlark J, Whitney K M, Lothrop Jr C D. A deletion mutation causes hemophilia B in Lhasa Apso dogs.  Blood. 1996;  88 3451-3455
• 13 Herzog R W, Mount J D, Arruda V R, High K A, Lothrop Jr C D. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.  Mol Ther. 2001;  4 192-200
• 14 Manno C S, Chew A J, Hutchison S et al.. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.  Blood. 2003;  101 2963-2972
• 15 Snyder R O, Miao C H, Patijn G A et al.. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.  Nat Genet. 1997;  16 270-276
• 16 Nakai H, Herzog R W, Hagstrom J N et al.. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver.  Blood. 1998;  91 4600-4607
• 17 Snyder R O, Miao C, Meuse L et al.. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.  Nat Med. 1999;  5 64-70
• 18 Wang L, Takabe K, Bidlingmaier S M, Ill C R, Verma I M. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.  Proc Natl Acad Sci USA. 1999;  96 3906-3910
• 19 Parker A, Nagy D, Vargas J et al.. In vivo performance of AAV2 vectors purified by CsCl gradient centrifugation or column chromatography.  Mol Ther. 2003;  7 S390
• 20 Miao C H, Ohashi K, Patijn G A et al.. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.  Mol Ther. 2000;  1 522-532
• 21 Kay M AHK, Glader B, Manno C S et al.. A phase I/II clinical trial for liver directed AAV-mediated gene transfer for severe hemophilia B.  Blood. 2002;  100 (suppl) 426
• 22 Wang L, Nichols T C, Read M S, Bellinger D A, Verma I M. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.  Mol Ther. 2000;  1 154-158
• 23 Mount J D, Herzog R W, Tillson D M et al.. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.  Blood. 2002;  99 2670-2676
• 24 Nathwani A C, Davidoff A M, Hanawa H et al.. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.  Blood. 2002;  100 1662-1669
• 25 Mingozzi F, Liu Y L, Dobrzynski E et al.. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.  J Clin Invest. 2003;  111 1347-1356
• 26 Nakai H, Iwaki Y, Kay M A, Couto L B. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver.  J Virol. 1999;  73 5438-5447
• 27 Grimm D, Zhou S, Nakai H et al.. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.  Blood. 2003;  102 2412-2419
• 28 Chiorini J A, Yang L, Liu Y, Safer B, Kotin R M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles.  J Virol. 1997;  71 6823-6833
• 29 Chiorini J A, Kim F, Yang L, Kotin R M. Cloning and characterization of adeno-associated virus type 5.  J Virol. 1999;  73 1309-1319
• 30 Gao G P, Alvira M R, Wang L, Calcedo R, Johnston J, Wilson J M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.  Proc Natl Acad Sci USA. 2002;  99 11854-11859
• 31 Rutledge E A, Halbert C L, Russell D W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.  J Virol. 1998;  72 309-319
• 32 Xiao W, Chirmule N, Berta S C, McCullough B, Gao G, Wilson J M. Gene therapy vectors based on adeno-associated virus type 1.  J Virol. 1999;  73 3994-4003
• 33 Duan D, Yan Z, Yue Y, Ding W, Engelhardt J F. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation.  J Virol. 2001;  75 7662-7671
• 34 Rabinowitz J E, Rolling F, Li C et al.. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.  J Virol. 2002;  76 791-801
• 35 Chao H, Liu Y, Rabinowitz J, Li C, Samulski R J, Walsh C E. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.  Mol Ther. 2000;  2 619-623
• 36 Chao H, Monahan P E, Liu Y, Samulski R J, Walsh C E. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.  Mol Ther. 2001;  4 217-222
• 37 Arruda V R, Schuettrumpf J, Herzog R W et al.. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.  Blood. 2003;  11 11
• 38 Mingozzi F, Schuttrumpf J, Arruda V R et al.. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.  J Virol. 2002;  76 10497-10502
• 39 Pittman D D, Tomkinson K N, Kaufman R J. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.  J Biol Chem. 1994;  269 17329-17337
• 40 Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.  Proc Natl Acad Sci USA. 1999;  96 12725-12730
• 41 Scallan C D, Liu T, Parker A E et al.. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.  Blood. 2003;  102 3919-3926
• 42 Chao H, Sun L, Bruce A, Xiao X, Walsh C E. Expression of human factor VIII by splicing between dimerized AAV vectors.  Mol Ther. 2002;  5 716-722
• 43 Gnatenko D V, Saenko E L, Jesty J, Cao L X, Hearing P, Bahou W F. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy.  Br J Haematol. 1999;  104 27-36
• 44 Chao H, Mao L, Bruce A T, Walsh C E. Sustained expression of human factor VIII in mice using a parvovirus-based vector.  Blood. 2000;  95 1594-1599
• 45 Sarkar R, Xiao W, Kazazian Jr H H. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.  J Thromb Haemost. 2003;  1 220-226
• 46 Couto L SC, Jiang H, Qian X et al.. Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector.  Blood. 2002;  100(suppl) 117a
• 47 Scallan C D, Lillicrap D, Jiang H et al.. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.  Blood. 2003;  102 2031-2037
• 48 Jiang H, Patarroyo-White S, Nagy D et al.. Improved efficacy in gene therapy of Hemophilia A using an AAV6 pseudo-typed FVIII vector.  Mol Ther. 2003;  7 S184-(abst)
• 49 Arruda V R, Fields P A, Milner R et al.. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.  Mol Ther. 2001;  4 586-592
• 50 Summerford C, Samulski R J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.  J Virol. 1998;  72 1438-1445
• 51 Couto L, Parker A, Gordon J. Direct exposure of mouse sperm to high concentrations of an adeno-associated virus gene therapy vector fails to lead to germ cell transduction.  Mol Ther. 2003;  7 S161 (abst)
• 52 Miller D G, Rutledge E A, Russell D W. Chromosomal effects of adeno-associated virus vector integration.  Nat Genet. 2002;  30 147-148
• 53 Nakai H, Yant S R, Storm T A, Fuess S, Meuse L, Kay M A. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.  J Virol. 2001;  75 6969-6976
• 54 Nakai H, Montini E, Fuess S, Storm T A, Grompe M, Kay M A. AAV serotype 2 vectors preferentially integrate into active genes in mice.  Nat Genet. 2003;  34 297-302
• 55 Moskalenko M, Chen L, van Roey M et al.. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.  J Virol. 2000;  74 1761-1766
• 56 Parks W BD, Melnick J, Taber L, Yow M. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses.  Infect Immun. 1970;  2 716-722
• 57 Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans.  Gene Ther. 1999;  6 1574-1583